Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures (2018 - 2023)

Dianthus Therapeutics has reported Gains from Sales and Divestitures over the past 2 years, most recently at $6495.0 for Q4 2023.

Quarterly results put Gains from Sales and Divestitures at $6495.0 for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $6495.0 (changed N/A YoY), and the annual figure for FY2023 was $6495.0, changed.
Gains from Sales and Divestitures for Q4 2023 was $6495.0 at Dianthus Therapeutics, roughly flat from $6495.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for DNTH hit a ceiling of $6495.0 in Q3 2023 and a floor of $6495.0 in Q3 2023.